The "Dust Mite (Dermatophagoides pteronyssinus) IgE" test measures your body's immune response to a common allergen found in household dust mites. Dust mites, tiny creatures invisible to the naked eye, thrive in warm, humid environments like bedding, carpets, and furniture. When you inhale or come into contact with dust containing these mites, your immune system may react by producing specific antibodies called IgE (Immunoglobulin E) if you’re sensitive to them.

Biomarkers:

- IAD/Methane Score

- PP Bacteria/Yeast

- Reference Variance

- Total Abundance

Therapeutic Support Options: 

Therapeutic support options are static to serve as potential treatment ideas. Clinician discretion is advised when selecting appropriate therapeutics for individual patients.

- Pre-/Probiotics

- Increase Dietary Fiber Intake

- Consider SIBO Testing

- Increase Resistant Starches

- Increase Fermented Foods

- Meal Timing

Genova’s data analysis has led to the development of unique dysbiosis patterns, related to key physiologic disruptions, such as immunosuppression and inflammation. These patterns may represent dysbiotic changes that could pose clinical significance. 

Ehrlichia chaffeensis antibody (IgG) testing is a critical diagnostic tool used to detect previous or ongoing infections with Ehrlichia chaffeensis, the bacterium responsible for human monocytic ehrlichiosis (HME), a potentially severe tick-borne disease.

The presence of IgG antibodies against E. chaffeensis in a patient's blood suggests an immune response to this specific pathogen. IgG antibodies are typically produced later in the course of an infection and can persist for a long period, often indicating past exposure or a more chronic form of the infection. In clinical settings, testing for E. chaffeensis IgG is particularly important for patients presenting with symptoms suggestive of HME, which include fever, headache, malaise, and sometimes more severe manifestations like thrombocytopenia, leukopenia, and elevated liver enzymes.

The E. Chaffeensis Ab IgG test is a specialized diagnostic tool pivotal in the field of infectious diseases, particularly in the context of tick-borne illnesses. Ehrlichia chaffeensis is the bacterium responsible for Ehrlichiosis, a condition transmitted through tick bites, primarily in regions where ticks are endemic. The IgG antibody test for E. chaffeensis plays a crucial role in the diagnosis and management of this infection.

Ehrlichia chaffeensis Ab (IgM) testing plays a critical role in the early diagnosis of human monocytic ehrlichiosis (HME), a tick-borne illness caused by the bacterium Ehrlichia chaffeensis. This test specifically looks for IgM antibodies, which are among the first antibodies produced by the immune system in response to an infection. The presence of IgM antibodies against E. chaffeensis typically indicates a recent or ongoing infection, as these antibodies usually develop within the first week or two after exposure to the bacterium and can be detected before the IgG antibodies.

The E. Chaffeensis Ab IgM test is a crucial diagnostic tool in the realm of infectious diseases, specifically for the timely detection of Ehrlichiosis, a tick-borne illness caused by the Ehrlichia chaffeensis bacterium. This test detects IgM antibodies, which are among the first antibodies produced by the immune system in response to an infection.

The Etiocholanolone/Androsterone (E/A) Ratio assesses androgen metabolism by comparing the enzymatic activity of 5b-reductase/5a-reductase. Etiocholanolone is produced via the 5b-reductase pathway and androsterone is produced via the 5a-reductase pathway.

The Etiocholanolone/Androsterone (E/A) Ratio assesses androgen metabolism by comparing the enzymatic activity of 5β-reductase/5α-reductase.

The Etiocholanolone/Androsterone (E/A) Ratio assesses androgen metabolism by comparing the enzymatic activity of 5β-reductase/5α-reductase.

The ratio of potentially toxic urinary estrogens (i.e. 2- and 4-catechols of estradiol and estrone) to inert estriol has been used for many years as an index of breast cancer risk.

The EBV (Epstein Barr) Nuclear Antigen Antibodies, IgG test looks for a type of antibody which the body typically develops in response to Epstein-Barr Virus.

EBNA antibodies usually appear 2-4 months after infection and persist for the life of the person.

This test is usually performed to establish a past infection with EBV.